Zobrazeno 1 - 10 of 136 pro vyhledávání: '"Di Nitto C"'
2
Akademický článek
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade.
Autor: Di Nitto C; Philochem AG, Otelfingen, Switzerland., Ravazza D; Philochem AG, Otelfingen, Switzerland., Gilardoni E; Philochem AG, Otelfingen, Switzerland., Look T; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland., Sun M; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland., Prodi E; Philochem AG, Otelfingen, Switzerland., Moisoiu V; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland., Pellegrino C; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland., Manz MG; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland., Puca E; Philochem AG, Otelfingen, Switzerland., Weller M; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Weiss T; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Neri D; Philogen SpA, Siena, Italy.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., De Luca R; Philochem AG, Otelfingen, Switzerland roberto.deluca@philogen.com.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Aug 13; Vol. 12 (8). Date of Electronic Publication: 2024 Aug 13.
Zobrazit plný text záznamu
3
Akademický článek
A Comparative Analysis of Fibroblast Activation Protein-Targeted Small Molecule-Drug, Antibody-Drug, and Peptide-Drug Conjugates.
Autor: Zana A; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland., Puig-Moreno C; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland.; Swiss Federal Institute of Technology, Department of Chemistry and Applied Biosciences, CH-8093 Zürich, Switzerland., Bocci M; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland., Gilardoni E; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland., Di Nitto C; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland., Principi L; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland., Ravazza D; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland., Rotta G; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland., Prodi E; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland., De Luca R; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland., Neri D; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland.; Swiss Federal Institute of Technology, Department of Chemistry and Applied Biosciences, CH-8093 Zürich, Switzerland.; Philogen S.p.A., 53100 Siena, Italy., Cazzamalli S; Philochem AG, R&D Department, Libernstrasse 3, CH-8112 Otelfingen, Zürich, Switzerland.
Publikováno v: Bioconjugate chemistry [Bioconjug Chem] 2023 Jul 19; Vol. 34 (7), pp. 1205-1211. Date of Electronic Publication: 2023 Jul 03.
Zobrazit plný text záznamu
4
Akademický článek
Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma.
Autor: Look T; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich 8091, Switzerland., Puca E; Philogen S.p.A, Sovicille 53018, Italy., Bühler M; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich 8091, Switzerland., Kirschenbaum D; Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel., De Luca R; Philogen S.p.A, Sovicille 53018, Italy., Stucchi R; Philogen S.p.A, Sovicille 53018, Italy., Ravazza D; Philogen S.p.A, Sovicille 53018, Italy., Di Nitto C; Philogen S.p.A, Sovicille 53018, Italy., Roth P; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich 8091, Switzerland., Katzenelenbogen Y; Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel., Weiner A; Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel., Rindlisbacher L; Institute of Experimental Immunology, University of Zurich, Zurich 8057, Switzerland., Becher B; Institute of Experimental Immunology, University of Zurich, Zurich 8057, Switzerland., Amit I; Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel., Weller M; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich 8091, Switzerland., Neri D; Philogen S.p.A, Sovicille 53018, Italy., Hemmerle T; Philogen S.p.A, Sovicille 53018, Italy., Weiss T; Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich 8091, Switzerland.
Publikováno v: Science translational medicine [Sci Transl Med] 2023 May 24; Vol. 15 (697), pp. eadf2281. Date of Electronic Publication: 2023 May 24.
Zobrazit plný text záznamu
5
Akademický článek
An Antibody Targeting Fibroblast Activation Protein Simultaneously Fused to Interleukin-2 and Tumor Necrosis Factor Selectively Localizes to Neoplastic Lesions.
Autor: Prodi E; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland.; CiBIO (Department of Cellular, Computational and Integrative Biology), University of Trento, 38123 Trento, Italy., Comacchio C; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland., Gilardoni E; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland., Di Nitto C; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland., Puca E; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland., Neri D; Philogen Spa, 53100 Siena, Italy., De Luca R; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland.
Publikováno v: Antibodies (Basel, Switzerland) [Antibodies (Basel)] 2023 Apr 14; Vol. 12 (2). Date of Electronic Publication: 2023 Apr 14.
Zobrazit plný text záznamu
6
Akademický článek
An Engineered IFNγ-Antibody Fusion Protein with Improved Tumor-Homing Properties.
Autor: Di Nitto C; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland., Gilardoni E; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland., Mock J; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland., Nadal L; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland., Weiss T; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland., Weller M; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland., Seehusen F; Laboratory for Animal Model Pathology (LAMP), Institute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland., Libbra C; Philogen S.p.A., Piazza La Lizza 7, 53100 Siena, Italy., Puca E; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland., Neri D; Philogen S.p.A., Piazza La Lizza 7, 53100 Siena, Italy., De Luca R; Philochem AG, Libernstrasse 3, 8112 Otelfingen, Switzerland.
Publikováno v: Pharmaceutics [Pharmaceutics] 2023 Jan 22; Vol. 15 (2). Date of Electronic Publication: 2023 Jan 22.
Zobrazit plný text záznamu
7
Akademický článek
Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody.
Autor: Nadal L; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland., Peissert F; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland.; Department of Biology and Biotechnology, IUSS, Pavia, Italy., Elsayed A; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland.; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Weiss T; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland., Look T; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland., Weller M; Department of Neurology and Clinical Neuroscience Center, University Hospital Zurich, Zurich, Switzerland., Piro G; Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy., Carbone C; Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy., Tortora G; Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.; Medical Oncology, Department of Translational Medicine, Catholic University of the Sacred Heart, Rome, Italy., Matasci M; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland., Favalli N; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland., Corbellari R; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland., Di Nitto C; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland., Prodi E; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland., Libbra C; Philogen SpA, Siena, Italy., Galeazzi S; Philogen SpA, Siena, Italy., Carotenuto C; Philogen SpA, Siena, Italy., Halin C; Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland., Puca E; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland., Neri D; Philogen SpA, Siena, Italy., De Luca R; Antibody Therapeutics, Philochem AG, Otelfingen, Zurich, Switzerland roberto.deluca@philogen.com.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Sep; Vol. 10 (9).
Zobrazit plný text záznamu
8
Akademický článek
Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21.
Autor: Di Nitto C; Philochem AG, 8112 Otelfingen, Switzerland., Neri D; Philochem AG, 8112 Otelfingen, Switzerland.; Philogen SpA, Piazza la Lizza 7, 53100 Siena, Italy., Weiss T; Department of Neurology, University Hospital Zurich, 8091 Zurich, Switzerland.; Clinical Neuroscience Center, University of Zurich, 8091 Zurich, Switzerland., Weller M; Department of Neurology, University Hospital Zurich, 8091 Zurich, Switzerland.; Clinical Neuroscience Center, University of Zurich, 8091 Zurich, Switzerland., De Luca R; Philochem AG, 8112 Otelfingen, Switzerland.
Publikováno v: Antibodies (Basel, Switzerland) [Antibodies (Basel)] 2022 Mar 04; Vol. 11 (1). Date of Electronic Publication: 2022 Mar 04.
Zobrazit plný text záznamu
9
Akademický článek
Intracellular label-free detection of mesenchymal stem cell metabolism within a perivascular niche-on-a-chip.
Autor: Perottoni S; Department of Chemistry, Materials and Chemical Engineering 'Giulio Natta', Politecnico di Milano, Piazza Leonardo da Vinci, 32 - 20133 Milan, Italy. simone.perottoni@polimi.it cesare.dinitto@mail.polimi.it manuela.raimondi@polimi.it., Neto NGB, Di Nitto C, Dmitriev RI, Raimondi MT, Monaghan MG
Publikováno v: Lab on a chip [Lab Chip] 2021 Apr 07; Vol. 21 (7), pp. 1395-1408. Date of Electronic Publication: 2021 Feb 19.
Zobrazit plný text záznamu
10
Akademický článek
Sentinels of neuroinflammation: the crucial role of myeloid cells in the pathogenesis of gliomas and neurodegenerative diseases.
Autor: Cómitre-Mariano, Blanca1,2 (AUTHOR), Vellila-Alonso, Gabriel2,3 (AUTHOR), Segura-Collar, Berta1,2 (AUTHOR), Mondéjar-Ruescas, Lucía1,2 (AUTHOR), Sepulveda, Juan M.1,3 (AUTHOR) sepulvedasanchez@seom.org, Gargini, Ricardo1,2 (AUTHOR) ricgargini.imas12@h12o.es
Publikováno v: Journal of Neuroinflammation. 11/22/2024, Vol. 21 Issue 1, p1-23. 23p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje